Science AI Journal
Medicine · Research topic

Open research questions in Cardiac Valve Diseases and Treatments

79 unresolved questions extracted from the limitations and future-work sections of 555 Cardiac Valve Diseases and Treatments papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • Study Limitations This study has some limitations that should be acknowl- edged. Medication changes during long-term follow-up were not systematically assessed, and the potential impact of longitudinal optimization of medical therapy on residual IMR and clinical outcomes could not be determined.

    Dynamic Changes and Prognostic Impact of Ischemic Mitral Regurgitation in Recurrent Myocardial Infarction · 2026 · DOI

  • Although clinical follow-up at 12 months was available for approximately 90% of patients, this approach does not account for event timing and may be susceptible to bias in the presence of incomplete follow-up.

    Comparative Analysis of Antithrombotic Strategies Following Valve-in-Valve Transcatheter Aortic Valve Implantation Using Real-World Registry Data · 2026 · DOI

  • Abstract Background and Aims The prognostic impact of new-onset left bundle branch block (LBBB) after transcatheter aortic valve replacement (TAVR) remains unclear.

    Prognostic Impact of New-Onset Left Bundle Branch Block After TAVR According to Preoperative Diastolic Dysfunction Severity · 2026 · DOI

  • Importance Current guidelines recommend consideration of surgical treatment for asymptomatic patients with severe mitral valve regurgitation, but the long-term prognosis and optimal treatment of those with moderate mitral regurgitation (MR) remain uncertain.

    Twenty-Five–Year Follow-Up of Quantified Mitral Regurgitation · 2026 · DOI

  • Although the available literature indicates that imaging-based planning, surgical precision, multidisciplinary awareness and timely revascularization are associated with improved outcomes, the evidence remains limited, highlighting the need for larger prospective studies and standardized reporting.

    Latrogenic Injury to the Left Circumflex Artery during Mitral Valve Surgery: A Narrative Review · 2026 · DOI

  • Background: Comparisons between transcatheter and surgical aortic valve replacement (TAVR or SAVR) in younger aortic stenosis (AS) patients are scarce.

    Transcatheter Versus Mechanical and Bioprosthetic Surgical Aortic Valve Replacement in Retrospective Patient Cohorts with Aortic Stenosis <75 Years · 2026 · DOI

  • diac conduction disturbances after transcatheter aortic valve replacement: much remains to be learned Nazif TM and Kodali SK FRE E C L I NI C AL R E SE AR C H 10.

    Glucocorticoids to reduce permanent pacemaker implantation after TAVI: the GLUCO-TAVI randomised trial · 2026 · DOI

  • Before TAVI, the patient’s tomographic and angiographic images should be examined thoroughly, and the access site should be determined according to a clearly defined strategy.

    Facilitating Transfemoral Transcatheter Aortic Valve Implantation in Severe Peripheral Artery Disease Using Iliac Stenting and Radiopaque Contrast Lubrication: A Case Report · 2026 · DOI

  • However, most of the previous studies focused on LA parameters for the description of atrial remodeling processes, whereas limited information is available on the role of the RA in patients with AF (9, 10).

    Case Report: Right-atrial reverse remodeling causing resolution of new-onset torrential tricuspid regurgitation after successful rhythm control · 2026 · DOI

  • High shear stress (HSS) generated by progressive valvular obstruction drives endothelial injury and immune-mediated inflammation, but the contribution of circulating T cells to AVS pathogenesis remains poorly defined.

    Aortic valve stenosis promotes pathological shear stress-dependent epigenomic dysregulation in circulating T cells. · 2026 · DOI

  • Our data have several limitations. First, in the pre-TAVI clinic period, we only received data for patients who ultimately underwent a TAVI procedure. This limited our ability to compare the proportion of referred patients who ultimately were accepted for a TAVI, or mortality between the pre- and post-TAVI clinic periods. Second, all the improvements in median time to TAVI may not have solely been due to improvements in our pathway, as during the same period, there were also significant im- provements in the procedural capacity of the tertiary centre. This is evi- denced by a significant decrease in median time from MDT discussion to TAVI between the pre- and post-TAVI clinic periods. However, the re- duction in median time from referral to MDT (113 days) was greater than the decrease in time from MDT to TAVI (36 days), suggesting much of the improvement in overall time to TAVI is likely due to improvements in our pathway. Finally, the findings from a regional TAVI referral network may not be directly generalisable to other healthcare systems.

    Improving time to TAVI with a local TAVI clinic: A single-centre quality improvement project · 2026 · DOI

  • This study has several strengths; it is the first study to describe the experiences of RHD patients with valve choice and anticoagulation. The survival follow-up data is robust and complete as it is obtained by linkage to national minimum datasets concerning mortality at Health New Zealand. This study has some limitations. The study was retrospective, selfreported and based on patient recall. This introduces recall bias; patients may not have accurately remembered information. Additionally, patient-reported perspectives may have been influenced by cognitive dissonance, whereby individuals rationalise their treatment decisions favourably despite associated drawbacks. Rheumatic heart disease (RHD) is disproportionately prevalent among populations of lower socioeconomic status, which may contribute to reduced patient contactability and an increased risk of complications due to limited access to healthcare services (13). These factors introduce the potential for both attrition bias and ascertainment bias within the study. in (MVRs) observed Although rheumatic heart disease is classically described as predominantly affecting the mitral valve, the higher proportion of aortic valve replacements (AVRs) compared with mitral valve replacements this cohort does not necessarily imply inclusion of degenerative aortic valve disease. The observed distribution is likely to reflect differences in disease progression and management strategies rather than true underlying prevalence. The NZ RHD registry (14) demonstrates that the burden of mixed mitral and aortic valve disease and of aortic valve disease alone increases in adulthood, consistent with the age profile of our cohort. In addition, percutaneous balloon mitral intervention is frequently utilised in New Zealand (most frequently in isolated mitral valve disease), and rheumatic mitral valve disease is often managed with repair, as evidenced by better long-term outcomes with equivalent durability to MVR (15). These factors limit the progression to requiring an MVR. In contrast, rheumatic aortic valve disease, particularly when presenting with significant regurgitation, frequently amenable to repair and more commonly requires valve replacement (16). Consequently, referral and intervention bias likely present, such that this cohort reflects patients are undergoing valve replacement rather than the full spectrum of rheumatic valve disease within the population.

    Patient perspectives of prosthetic heart valve choice and anticoagulation in patients with rheumatic heart disease: a semi-quantitative study · 2026 · DOI

  • Several limitations of our study should be acknowledged. First, the retrospective and predominantly observational study design inherently limits the ability to establish causality. Second, there is a potential survivor bias, as the study only included patients who survived long enough to undergo the second aortic valve intervention, which may not accurately reflect outcomes in the broader population. Third, the measurement of Lp(a) was performed at a single time point, specifically at the time of reintervention, which limits insights into potential temporal variations or trends in Lp(a) levels over time. Fourth, while most Lp(a) values were measured in nmol/L, a subset origi- nally reported in mg/dL was converted using a standard fac- tor. Given that these units capture distinct biological attributes (particle number versus mass), such conversion is inherently imprecise and represents a methodological limitation of the present study. Finally, we did not have the statistical power to show any detrimental effects on bioprostesis degeneration that precipitate only at extremely high circulating levels of Lp(a).

    Impact of lipoprotein(a) on the durability of aortic bioprosthetic valves · 2026 · DOI

  • This study is subject to the limitations of its observational and retrospective design. Although derived from a large multicenter registry, procedural and echocardiographic data were site-reported and not adjudicated by a core lab- oratory. Details on previous cardiac surgery were limited, precluding stratified analyses by surgical type or timing. As such, findings should be interpreted with caution and warrant validation in prospective studies.

    Impact of Previous Cardiac Surgery on Outcomes After Tricuspid Valve Transcatheter Edge-to-Edge Repair: Insights from EuroTR · 2026 · DOI

  • The convergence of chronic hyperlipidemia on similar transcriptional and intercellular communication changes across both Ldlr−/− and Apoe−/− models suggests shared mechanistic pathways; however, direct comparison of lipid composition, lipid oxidation products, and their differential effects on VIC Spp1+ activation and ECM programs between these models has not been performed.

    Osteopontin-expressing valvular interstitial cell subpopulation as a driver of extracellular matrix remodeling in aortic valve disease · 2026 · DOI

  • While CellChat analysis demonstrates elevated collagen, fibronectin, and osteopontin signaling pathways in VIC Spp1+ cells under both Ldlr−/− and Apoe−/− hyperlipidemic conditions, mechanistic studies investigating how collagen-integrin axes (α2β1, β1) specifically amplify the pro-fibrotic phenotype and stress fiber formation in this subpopulation are absent.

    Osteopontin-expressing valvular interstitial cell subpopulation as a driver of extracellular matrix remodeling in aortic valve disease · 2026 · DOI

  • NicheNet analysis identified ICAM1-ITGB2 axis engagement between immune cells and VIC Spp1+ under hyperlipidemia, suggesting LFA-1-mediated pro-osteogenic signaling; however, the specific contribution of dendritic cells, macrophages, and T cell subsets to this immune-fibroblast interaction and ECM remodeling in AVD models requires systematic interrogation.

    Osteopontin-expressing valvular interstitial cell subpopulation as a driver of extracellular matrix remodeling in aortic valve disease · 2026 · DOI

  • The α10β1 integrin heterodimer is characterized as abundant in cartilaginous tissues and involved in VIC Spp1+ autocrine collagen signaling in Ldlr−/− mice, but its specific role in collagen-dependent VIC activation and matrifibroblast differentiation during aortic valve disease progression has not been directly tested.

    Osteopontin-expressing valvular interstitial cell subpopulation as a driver of extracellular matrix remodeling in aortic valve disease · 2026 · DOI

  • While NFE2L1 regulon activation is robustly identified in VIC Spp1+ cells across both Ldlr−/− and Apoe−/− hyperlipidemic models through pySCENIC analysis, evidence for NFE2L1's role in human AVD, functional manipulation in VIC/VEC culture models, or genetic association analyses in human patient cohorts remains to be established.

    Osteopontin-expressing valvular interstitial cell subpopulation as a driver of extracellular matrix remodeling in aortic valve disease · 2026 · DOI

  • Studies addressing the role of Sdc4 (syndecan-4) in aortic valve disease are lacking, despite NicheNet analysis predicting Sdc4-dependent communication in VIC Spp1+ cells under hyperlipidemic conditions. The potential contribution of Sdc4 to abnormal ECM remodeling in aortic stenosis through its functions as a mechanotransducer and focal adhesion regulator requires direct investigation in AVD models.

    Osteopontin-expressing valvular interstitial cell subpopulation as a driver of extracellular matrix remodeling in aortic valve disease · 2026 · DOI

  • The study observed opposing patterns of CR use: lower CR attendance among clinically unstable patients but higher use among functionally limited but clinically stable individuals, contrasting with USA findings where poorer functional status reduced CR participation. This discrepancy in referral practices and clinical decision-making across different settings requires targeted investigation to clarify optimal patient selection strategies for post-TAVI cardiac rehabilitation.

    Cardiac rehabilitation after transcatheter aortic valve implantation before, during and after the COVID-19 pandemic: a whole-population study · 2026 · DOI

  • Strong inequities in CR attendance were identified: patients from the least deprived areas were 26-43% more likely to attend than those from most deprived areas, and males were 22% more likely to attend than females. Future research must explore alternative models of care (as used successfully in post-ACS and heart failure populations) specifically designed to ensure equitable access for female TAVI patients and those from socioeconomically disadvantaged areas.

    Cardiac rehabilitation after transcatheter aortic valve implantation before, during and after the COVID-19 pandemic: a whole-population study · 2026 · DOI

  • Substantial regional variation in CR attendance across England exists, yet the health system factors and referral practices driving this variation have not been characterised. Future research should identify which system-level factors explain regional disparities in TAVI cardiac rehabilitation uptake and develop standardised eligibility and referral processes across health systems.

    Cardiac rehabilitation after transcatheter aortic valve implantation before, during and after the COVID-19 pandemic: a whole-population study · 2026 · DOI

  • The evidence supporting cardiac rehabilitation in the post-TAVI population remains scarce with no formal guidelines for postdischarge management. Future studies must validate the clinical benefit of CR specifically in TAVI patients and establish the most appropriate clinical criteria for CR referral to overcome the current perception that CR may be unnecessary given rapid discharge within days.

    Cardiac rehabilitation after transcatheter aortic valve implantation before, during and after the COVID-19 pandemic: a whole-population study · 2026 · DOI

  • CR exposure was classified using outpatient electronic medical record data subject to coding variability across hospitals, yet standardised referral criteria and programme protocols for CR after TAVI do not exist. Future linkage between NHS electronic records and the National Audit of Cardiac Rehabilitation (NACR) database would advance validation of CR exposure classification and enable direct comparison of rehospitalisation and mortality outcomes.

    Cardiac rehabilitation after transcatheter aortic valve implantation before, during and after the COVID-19 pandemic: a whole-population study · 2026 · DOI

Most-cited papers in Cardiac Valve Diseases and Treatments

Most recent work

Find a gap in your own Cardiac Valve Diseases and Treatments sub-topic

This page shows what the Cardiac Valve Diseases and Treatments literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Substance Abuse Treatment and Outcomes
989 open questions
Artificial Intelligence in Healthcare and Education
607 open questions
Attention Deficit Hyperactivity Disorder
448 open questions
Physical Activity and Health
436 open questions
Smoking Behavior and Cessation
402 open questions
Innovations in Medical Education
364 open questions
Dementia and Cognitive Impairment Research
363 open questions
HIV/AIDS Research and Interventions
342 open questions
79 open questions have been extracted from the limitations and future-work passages of 555 Cardiac Valve Diseases and Treatments papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.